Our
Company
NorthStar is a radiopharmaceutical company, developing novel ways to help detect and cure cancer and other serious diseases. We are the first and only U.S. company housing commercial scale radioisotope production and radiopharmaceutical CDMO services co-located on the same campus.
We are routinely producing radioisotopes including Actinium-225 (Ac-225) and Copper-67 (Cu-67), used in drug development and clinical trials for the treatment of several types of cancer.
CREATIVE SOLUTIONS, WE
CLEARLY DEFINE
WHO
WE ARE
WE ARE
We are innovators who have transformed U.S. production of Cu-67 and Ac-225, advancing non-uranium methods that protect the environment. As pioneers in the field, we collaborate with industry leaders to develop and commercialize next-generation diagnostics and radiopharmaceutical therapies that will drive the future of patient care.
But our innovation goes far beyond isotope production. We are problem-solvers—delivering tailored solutions that guide customers through the complexities of radiopharmaceutical development and manufacturing. Our team includes leaders in nuclear medicine, early drug development, engineering, and quality assurance. Above all, we are driven by a passion to expand patient access to life-changing radiopharmaceuticals.
